Elicera Therapeutics

T cells attacking cancer
#CAR-T #Elicera Therapeutics #Lung cancer #Oncology #Partnership #Skin cancer #T cell receptor (TCR)

Collaborators investigate novel T-cell receptor therapy

Elicera Therapeutics has entered a Material Transfer Agreement (MTA) with a prominent US cancer centre to evaluate the enhancing effect of the iTANK-technology in a novel T-cell receptor therapy targeting skin cancer and lung cancer. Elicera Therapeutics will make parts of its technology iTANK available to… Read More

#Cancer Research #News

Blood samples in lab
#Blood cancer #CAR-T #Cell and gene therapy #Elicera Therapeutics #Phase I trial #Swedish Medical Products Agency

CAR-T therapy for B-cell lymphoma enters trials in Sweden

Cell and gene therapy company Elicera Therapeutics has received approval from the Swedish Medical Products Agency to start the clinical Phase I/II study CARMA in patients with B-cell lymphoma who no longer respond to standard treatment or have relapsed. CARMA is a single-arm, unblinded, multicentre study… Read More

#Cancer Research #News